Hims & Hers: Still Trading At A Massive Discount
Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...
Hims & Hers Stock: Growth, Noise, and Where to Focus Now
Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a ...
IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List
Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no ...
Hims & Hers: FDA Ruling May Close Compounded GLP-1 Drug 'Loophole', It Was Fun While It Lasted
Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...
Hosted on MSN2d
Why "Hims and Hers" Stock Plummeted
The Short discusses a 15% drop in Hims & Hers stock following an FDA announcement ending the shortage of Eli Lilly's weight ...
Hims & Hers Stock Skyrockets 200%, Then Is Crashing--What's Next for This Telehealth Powerhouse?
CNBC’s Jim Cramer suggested on Tuesday that NVIDIA Corp. (NASDAQ:NVDA) may have reached a key turning point after the stock ...
Strong Buy Recommendation for Hims & Hers Health Amid Growth Potential and Market Volatility
Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated ...
SchaeffersResearch.com6d
Hims and Hers Health Stock Testing Key Trendline
HIMS is on track for its worst single-session decline since Nov. 14, when Amazon.com (AMZN) entered the telehealth services ...
Hims & Hers Health: Sell Rating Due to Compounding Exemption Risks and Uncertain GLP-1 Contributions
Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health (HIMS – Research Report), retaining the ...
Eli Lily GLP-1 shortage ends, FDA says: Hims & Hers stock falls
Hims & Hers Health (HIMS) shares tumble after the US Food and Drug Administration (FDA) announced that the shortage in Eli ...
The 10 most surprising health findings from 2024
Hims recaps the year's most surprising health findings, from the growing number of adults who consider monogamy optional to ...
Hims & Hers Health Are Falling Today: What's Going On?
Hims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a new decision regarding the status of tirzepatide injection shortages, which have ...